2315 Stock Overview
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.74 |
| 52 Week High | HK$27.80 |
| 52 Week Low | HK$5.74 |
| Beta | 0 |
| 1 Month Change | -11.03% |
| 3 Month Change | -20.21% |
| 1 Year Change | -67.88% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.23% |
Recent News & Updates
Shareholder Returns
| 2315 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 14.7% | 5.7% | 3.6% |
| 1Y | -67.9% | -40.7% | -10.1% |
Return vs Industry: 2315 underperformed the Hong Kong Biotechs industry which returned -41.4% over the past year.
Return vs Market: 2315 underperformed the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
| 2315 volatility | |
|---|---|
| 2315 Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2315's share price has been volatile over the past 3 months.
Volatility Over Time: 2315's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,066 | Yuelei Shen | biocytogen.com.cn |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH003, a humanized IgG2 agonistic monoclonal antibody targeting the CD40, a costimulatory protein found on antigen-presenting cells; and YH001, a humanized anti-CTLA-4, IgG1 monoclonal antibody. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human OX40 receptor; H004, a humanized IgG1 anti-4-1BB Agonists; YH005, an anti-Claudin 18.2 antibody; and YH008, an anti-PD-1/CD 40 bi-specific antibody for the treatment of solid tumors.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Fundamentals Summary
| 2315 fundamental statistics | |
|---|---|
| Market cap | HK$3.09b |
| Earnings (TTM) | -HK$413.95m |
| Revenue (TTM) | HK$774.94m |
4.0x
P/S Ratio-7.5x
P/E RatioIs 2315 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2315 income statement (TTM) | |
|---|---|
| Revenue | CN¥716.91m |
| Cost of Revenue | CN¥206.00m |
| Gross Profit | CN¥510.91m |
| Other Expenses | CN¥893.86m |
| Earnings | -CN¥382.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 71.27% |
| Net Profit Margin | -53.42% |
| Debt/Equity Ratio | 44.4% |
How did 2315 perform over the long term?
See historical performance and comparison